DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

Wedbush Maintains Outperform on Epizyme, Raises Price Target to $30

Wedbush maintains Epizyme (NASDAQ:EPZM) with a Outperform and raises the price target from $24 to $30.

Benzinga · 01/24/2020 13:23

Wedbush maintains Epizyme (NASDAQ:EPZM) with a Outperform and raises the price target from $24 to $30.